Clinical Trials Logo

Healthy Participants clinical trials

View clinical trials related to Healthy Participants.

Filter by:

NCT ID: NCT05626439 Completed - Clinical trials for Healthy Participants

A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants

Start date: December 28, 2022
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the relative bioavailability of alprazolam in plasma following a single dose of Staccato alprazolam compared to a single dose of oral alprazolam under fasted conditions

NCT ID: NCT05615012 Completed - Clinical trials for Healthy Participants

A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants

Start date: November 11, 2022
Phase: Phase 1
Study type: Interventional

The aim of this study is to assess the effect of coadministration of multiple oral doses of BMS-986322 with rosuvastatin, metformin, and methotrexate in healthy participants.

NCT ID: NCT05604287 Recruiting - Clinical trials for Healthy Participants

Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects

Start date: October 10, 2022
Phase: Phase 1
Study type: Interventional

This study will evaluate safety, tolerability, and Pharmacokinetics (PK) of ID119031166M with the Exploration of Pharmacodynamic (PD) effects in Healthy Participants.

NCT ID: NCT05599828 Completed - Clinical trials for Healthy Participants

A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

Start date: July 17, 2020
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the PK of AMG 510 alone and in combination with either famotidine or omeprazole in healthy participants under fed conditions.

NCT ID: NCT05598281 Completed - Clinical trials for Healthy Participants

Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy Participants

Start date: November 5, 2019
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to evaluate the PK of digoxin administered alone and in combination with AMG 510 in healthy participants.

NCT ID: NCT05595434 Not yet recruiting - Clinical trials for Healthy Participants

Reality-monitoring & Stress

REALIST
Start date: April 30, 2024
Phase: N/A
Study type: Interventional

Reality-monitoring is a crucial cognitive process in daily life to remember the source of an information. Deficits of reality-monitoring have been shown into the continuum of schizophrenia, suggesting a preexisting alteration in population at-risk for psychosis that will be exacerbated during psychotic transition. It is admitted that stress plays a crucial role in the psychotic transition and can alter cognitive performances. However, less is known about the effects of stress on reality-monitoring, even though this process appears to be central in psychotic disorders. The aim of this project is to investigate the effect of stress on reality-monitoring, both on behavioral and neurophysiological aspects

NCT ID: NCT05581992 Completed - Clinical trials for Healthy Participants

Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

Start date: January 6, 2020
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the PK profile of AMG 510 alone and in combination with omeprazole in healthy participants.

NCT ID: NCT05581758 Completed - Clinical trials for Healthy Participants

A Study to Assess the Effect of Food on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

Start date: November 14, 2019
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to evaluate the PK of AMG 510 administered in the fasted and fed state in healthy participants.

NCT ID: NCT05579860 Completed - Clinical trials for Healthy Participants

A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants

Start date: October 5, 2022
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the bioequivalence of olezarsen between 2 subcutaneous (SC) formulations [(autoinjector (AI) and vial] at 2 dose levels in healthy adult participants.

NCT ID: NCT05579574 Completed - Clinical trials for Healthy Participants

A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants

Start date: October 21, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect of multiple doses of BMS-986322 on the pharmacokinetics (PK) of Loestrin components in healthy female participants.